AI-Native Scoping Reviews & Evidence Mapping

This review shows that aortic dissection treatment is no longer a simple “Type A surgery, Type B medicine” paradigm: outcomes now depend on timing, anatomy, malperfusion, remodeling strategy, and lifelong surveillance. The full paper is worth reading because it maps where TEVAR, open surgery, hybrid repair, medical stabilization, and emerging pharmacological strategies truly change survival—and where uncertainty still demands careful patient selection.

Aortic dissection is not predicted by diameter alone: hypertension, genetics, aortic geometry, pregnancy, medications, sleep apnea, inflammation, and environmental triggers all reshape individual risk. The full paper is worth reading because it maps where classic thresholds fail — and where modern risk stratification may prevent missed catastrophic events.

Aortic dissection prognosis is not determined by anatomy alone: early malperfusion, shock, inflammatory activation, renal injury, and false-lumen remodeling sharply define survival risk. This review maps 173 references to show which clinical, biomarker, genetic, and imaging signals can guide urgent triage, TEVAR/open-surgery strategy, and long-term surveillance intensity.

Aortic dissection prevalence is not one number — it changes dramatically by clinical setting, genetics, anatomy, sleep apnea, mental health burden, and referral selection. This review is worth reading because it maps where “rare disease” thinking fails and where targeted screening may reveal preventable high-risk phenotypes.

This review shows that aortic dissection diagnosis is no longer just “CTA or miss it” — the strongest modern pathway combines ADD-RS, D-dimer, ECG-gated CTA, bedside ultrasound, and selective AI/biomarker triage. The full paper is worth reading because it maps exactly where diagnosis still fails — atypical symptoms, stroke-like presentations, intramural hematoma, transfer misinterpretation — and which tools can realistically close those gaps.

Angioscopy emerges as the vascular “direct vision” tool that reveals what angiography often misses: thrombus, plaque rupture, yellow vulnerable plaques, incomplete stent healing, and embolic aortic sources. The full review is worth reading because it maps where this old but powerful technology still has modern clinical value — from coronary risk prediction and DES healing to carotid surgery, bypass quality control, flow-diverter follow-up, and cryptogenic stroke work-up.

AAA risk is not just “age and diameter”: this review shows smoking as the dominant driver, diabetes as a paradoxically protective signal, and women as lower-prevalence but higher-risk patients once aneurysm develops. The full evidence map explains which biological, anatomical, genetic, and post-EVAR surveillance signals may move AAA risk assessment beyond diameter alone.

Abdominal aortic aneurysm is becoming less common in routine population screening, but prevalence remains sharply concentrated in older male smokers, first-degree relatives, and patients with vascular or cardiopulmonary disease. This review maps where AAA is now rare, where it is still unexpectedly frequent, and why future screening may need to become more targeted than universal.

Cystic adventitial disease is a rare but clinically important vascular mimic of atherosclerosis, aneurysm, and embolic disease — especially in younger patients with claudication and few cardiovascular risk factors. This SAIMSARA evidence map compresses scattered case-level evidence into a practical diagnostic and treatment roadmap, linking popliteal dominance, synovial/articular origin theories, imaging clues, recurrence risk, and surgical versus percutaneous strategies.